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Abstract
Background: Recent randomized controlled trial (RCTs) comparing percutaneous 
closure with antithrombotic treatment in patients with patent foramen ovale (PFO) 
and cryptogenic stroke revealed inconsistent results. Indeed, there is still no 
consensus on the management of these patients, namely closure or medical 
therapy treatment.
Methods: To take stock of the PFO management after cryptogenic stroke, we 
conducted a literature review that included 16 articles dealing with different 
therapeutic strategies and long‑term outcomes of these results.
Results: The reviewed studies showed great methodological diversity rendering 
an exhaustive and balanced comparison between studies difficult. Low recurrence 
rates under prevention regimens, crossovers, procedure‑ and device‑related 
complications, as well as inappropriate patient selection might explain the 
inconsistency of trials. However, despite the methodological heterogeneity certain 
patterns could be detected. It appears that device closure as secondary prevention 
measure is an effective and safe procedure reducing the recurrence of neurological 
events in cryptogenic stroke patients <60 years with large PFOs. Standardization 
of procedures and larger trials are needed to arrive to definitive conclusions.
Conclusion: In cryptogenic stroke patients <60 years with large PFOs, PFO closure 
seems to be safe and more effective compared to medical treatment alone. For 
all other patients group, for example, patients >60 years further trials are needed 
to clarify the role of PFO closure.
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INTRODUCTION
The prevalence of stroke remains a global 
scourge (approximately 12 million strokes worldwide 
in 2010), despite considerable therapeutic advances in 
recent years.[9] Previous studies have demonstrated the 
relationship between a patent foramen ovale (PFO) and 
cryptogenic stroke, especially in patients aged >55 years 
who also had an atrial septal aneurysm (ASA) or an 
important right‑to‑left shunt.[2,3,6,10,11,18]
However, not all of these PFOs are pathogenic, in 30% 
of these patients the PFO is an incidental finding.[2] In 
September 1995,[13] the Amplatzer septal occluder was 
introduced as the first human percutaneous closure of 
PFO. Since then, numerous trials have been conducted, 
including five recent randomized trials comparing 
percutaneous closure with antithrombotic treatment that 
revealed inconsistent results – some of them were in favor 
of closure, whereas others showing no difference.[4,5,14]
Our objective was to carry out a literature review to evaluate 
the role of PFO closure in different patients group.
MATERIALS AND METHODS
We conducted a PubMed research that included all 
papers concerning PFO associated with stroke. We 
selected only articles written in English language by 
using the following key words: “stroke,” “patent foramen 
ovale,” “atrial septal defect,” and “device closure PFO.” 
Key words were used in different combinations: “patent 
foramen ovale” and “stroke.” We chose only original 
studies including five randomized‑controlled trials (RCT) 
and case series on management of PFO after cryptogenic 
stroke. We included 12 articles for the purpose of this 
review. To provide better overview we extracted the data 
and tabulated the data for demographics, results, and 
complications [Tables 1 and 2]. In a separate section we 
provide summaries of each study.
RESULTS
Studies diverted greatly for size and methodology. 
Despite this, certain patterns could be identified through 
a systematic analysis of the selected studies. There were 
five RCTs,[4,12,14,17,19] two meta‑analysis,[1,8] and prospective 
case series,[15,21] including one propensity score‑matched 
analysis.[20] The total number of patients based on our 
included studies were 25179 subjects (2393 female and 
3543 male) with a mean age of 48.1 years (standard 
deviation (SD) 4.6). Mean study size was 2098.25 
subjects (SD 3538.1) with a mean follow up of 
51.4 months (SD 30.08). In summary, observational 
studies showed a significant superiority of device closure 
compared to medical therapy alone.[1,8,20] However, they 
are prone to selection bias and do not provide the quality 
of RCTs. The first three RCTs did not find any difference 
between device closure and medical treatment,[4,5,14] 
whereas long‑time data of the RESPECT trial, the 
CLOSE, and the REDUCE trial were finally in favor of 
device closure.[12,17,19]
Observational studies
Kitsios et al.[8] conducted a systematic review of 
observational and randomized evidence of secondary 
stroke prevention by percutaneous closure of PFO or 
medical therapy. They included in their review 52 single 
arm studies, 7 comparative non‑randomized trials, and 
the CLOSURE I trial (the first RCT on device closure). 
They found 0.36 recurrent cerebrovascular events (stroke 
and transient ischemic attack (TIA)) per 100 person–years 
(95% confidence interval (CI), 0.24–0.56) for closure 
patients versus 2.53 events (95% CI, 1.91–3.35) for medical 
therapy patients. Percutaneous closure was superior to 
medical treatment in comparative observational studies 
(IR ratio = 0.19, 95% CI, 0.07–0.54), which was not the 
case in the CLOSURE I trial. In the CLOSURE I study, 
the rate of recurrence was higher in the closure arm than 
the summary of recurrent event from observational studies.
Agarwal et al.[1] performed a meta‑analysis of transcatheter 
closure versus medical therapy for secondary prevention 
of recurrent cerebrovascular event after paradoxical 
embolism. They included 48 observational studies 
of 10.327 patients who had a cryptogenic stroke or a 
TIA. The primary outcome of the study reported was a 
recurrent stroke or TIA. Procedural failure, device‑related 
complications, and residual shunting post procedure were 
the secondary outcomes. The results showed that the risk 
of recurrent cerebral events was significantly lower in the 
closure group compared to medical therapy (RR 0.25, 
95% CI, 0.11–0.58, Ι² =66%, 10 studies). The incidence 
of recurrent cerebral events was 0.76 per 100 patients 
per year (95% CI, 0.48–1.05) for transcatheter closure 
and 4.39 per 100 patient years (95% CI, 3.20–5.59) for 
medical therapy.
Wahl et al.[20] conducted a propensity score‑matched 
comparison between PFO closure and medical treatment 
in 308 patients with cryptogenic stroke or TIA. 
One‑hundred and fifty patients underwent PFO closure 
and 108 received a medical treatment with a median 
follow up of 10 years. A composite of stroke, TIA, or 
peripheral embolism was defined as the primary outcome. 
It occurred in 11% of patients of PFO closure group and 
21% in patients of medical therapy group (P = 0.033). 
The low event rate in favor of closure PFO was due to 
a low rate of TIA, 5% versus 14% in the medical therapy 
group (P = 0.039). The risk of all‑cause mortality and 
cardiovascular mortality was similar in both groups.
Randomized studies
Furlan et al.[5] reported data of the CLOSURE I a 
multicenter, randomized, open‑label trial of closure with 
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Table 1: Demographics of studies included in the review
Author 
(first)
Reference Year Trial Study 
size
Female/
Male
Mean 
age
Co‑morbidities Follow‑up 
(in months)
Carroll 4 2013 Prospective, 
randomized, 
multicenter trial
980 444/536 46 1) diabetes mellitus 2) systemic hypertension 3) 
current smoker (13,3%) and former somker (28,3%) 
4) hypercholesterolemia 5) coronary artery disease 6) 
previous myocardial infarction 7) peripheral vascular 
disease 8) previous transient ischemic attack 9) previous 
stroke 10) family history of stoke 11) migraine 12) deep 
vein thrombosis 13) congestive heart failure 14) COPD 
14) hormone replacement therapy
30
Furlan 5 2012 Prospective study 909 438/471 46 1) hypertension 31% 2) hypercholesterolemia 44% 
3) family history of cardiovascular disease 55% 4) 
congestive heart disease 0,2% 5) coronary artery 
disease 1% 6) previous myocardial infarction 1,3% 
7) valvular dysfunction 10,3% 8) arrythmia 5% 9) 
catherization 4,4% 10) PTCA 0,9% 11) peripheral 
vascular disease 1,3% 12) Stokes Adams syndrome 
0,8% 13) pulmonary embolus 0,4% 14) pericarditis 
0,6% 14) cardiomyopathy 0,1% 15) smoking during the 
previous year 22%
24
Meier 14 2013 Prospective, 
randomized, 
multicenter study
414 208/206 44 1) family history of cerebrovascular event 22,4% 2) 
current smoker 23,9% 3) hypertension 25,8% 4) diabetes 
mellitus 2,6% 5) hypecholesterolemia 27% 6) valvular 
heart disease 3,1% 7) peripheral vascular disease 3,1% 
8) coronary artery disease 1,9% 9) history of myocardial 
infarction 1% 10) migraine 20,5% 
48
Windecker 21 2000 Prospective study 80 30/50 52 NM 60
Saver 17 2017 Multicenter, 
randomized 
prospective trial
980 444/536 46 1) diabetes mellitus 7,6% 2) arterial hypertension 
31,9% 3) current smoker 13,3%/former smoker 
28,3% 4) hypercholesterolemia 39,9% 5) peripheral 
vascular disease 0,6% 6) coronary artery disease 
2,9% 7) family history of stroke 25,1% 8) myocardial 
infarction 0,7% 9) previous stroke 10,6% 10) 
previous TIA 12,1% 11) migraine 38,9% 12) deep 
vein thrombosis 3,6% 13) congestive heart failure 
0,3% 14) COPD 1,1%
70
Mas 12 2017 multicenter, 
randomized, 
open‑label, 
prospective study
663 178/485 43 1) diabetes mellitus (3%) 2) arterial hypertension (13%) 
3) current smoker (36%) 4) hypercholesterolemia (17%) 
5) migraine (37%) 6) stroke (4%) 7) deep vein thrombosis 
or pulmonary embolism (2%) 8) myocardial infarction 
(0,01%) 9) obesity (15%)
63
Mono 15 2004 Retrospective 
study
308  44/264 51 1) arterial hypertension (46%) 2) diabetes mellitus (11%) 
3) smoking (49%) 4) hypercholesterolemia
48
Kitsios 8 2012 Meta analysis, 52 
single‑arm studies, 
7 comparative 
nonrandomized 
studies, CLOSURE I 
trial reviewed
8916 NM 47 1) arterial hypertension 2) diabetes mellitus 3) current 
smoking 4) hypercholesterolemia
NM
Argawal 1 2012 Meta analysis, 
48 observationnal 
studies
10327 NM NM 1) hypertension 6 to 51,6% 2) hypercholesterolemia 3) 
diabetes 4) ASA 4,5 to 62%
NM
Wahl 20 2012 Prospective, 
Propensity 
score‑matched 
analysis
308 44/264 51 1) arterial hypertension (46%) 2) diabetes mellitus (11%) 
3) smoking (49%) 4) hypercholesterolemia
120
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cohort, the rate of primary end point was significantly 
different between the closure group (0.39 events per 
100 patient–years) and the medical therapy group 
(1.45 events per 100 patients–years) (P = 0.007).
Concerning secondary end point, complete PFO closure 
at 6 months was reached in 72.7% of patients and 93.5% 
met criteria for effective closure (defined as a shunt 
grade of 0 or 1).
Saver et al.[17] reported the long‑term outcomes of 
the RESPECT trial patients. The mean follow up 
was 6 years. The primary efficacy end point included 
non‑fatal and fatal ischemic stroke and early death after 
randomization. Eighteen patients (3.6%) in the closure 
group had a recurrent ischemic stroke versus 28 (5.8%) in 
the medically treated group (P = 0.046).
Meier et al.[14] investigated the best therapeutic option 
in secondary prevention of a cryptogenic embolism in 
a randomized, multicenter, prospective study. The PC 
trial included 414 patients divided into two groups: 204 
in the closure group with an average age of 44 years 
and 210 patients in the medical therapy group with a 
mean age of 45 years. The mean follow up was 4 years. 
The primary end point was defined by a composite of 
death, a non‑fatal stroke, TIA, or peripheral embolism. 
Patients of the closure group were also medically treated 
with acetylsalicylic acid at 100–325 mg daily for at 
least 5–6 months in combination with ticlopidine at 
250–500 mg daily or clopidogrel at 75–150 mg daily for 
1–6 months. Patients in the second group were treated 
with antiplatelet therapy or oral anticoagulation with at 
least one antithrombotic drug. About 3.4% of patients in 
the closure group presented one of the primary end point 
versus 5.2% in the medical therapy group (P = 0.34). 
One patient (0.5%) of the closure group presented a 
non‑fatal stroke versus five patients (2.4%) in the second 
group (P = 0.14) and respectively five patients (2.5%), 
and seven patients (3.3%) presented at TIA (P = 0.56). 
Two patients (1.0%) died from a non‑cardiovascular death 
in the closure group versus no patient in the medical 
therapy group (P = 0.24).
Mas et al.[12] investigated in the CLOSE trial (randomized 
and prospective) the best therapeutic option for patients 
percutaneous device compared with medical therapy 
alone in a total of 909 patients who presented with a 
cryptogenic stroke or TIA and had a PFO. Four‑hundred 
and five patients had attempted implantation of the 
STARFlex device with 89.4% success rate. Primary end 
point was defined as a composite of stroke or TIA during 
2 years of follow‑up, death from any cause during the first 
30 days, or death from neurologic causes between 31 days 
and 2 years. The primary end point was achieved in 5.5% 
in the closure group (447 patients) compared to 6.8% in 
the medical therapy group (462 patients, P = 0.37). No 
death was reported in 30 days in either group, and there 
were no deaths from neurologic causes during the 2 year 
follow‑up period. Effective closure was documented in 
86.1% patients at 6 months. In 20 patients in the closure 
group and 22 patients in the medical group an alternative 
cause more likely than paradoxical embolism for the 
recurrent cerebrovascular found.
Carroll et al.[4]  investigated in a prospective, multicenter, 
randomized trial (RESPECT) on 980 patients (mean 
age of 45.9 years) with cryptogenic stroke whether device 
closure is superior to medical therapy alone in preventing 
recurrent ischemic stroke or early death by using the 
Amplatzer PFO occluder. Patients medically treated 
received one or more antiplatelet medications (74.8%) 
or were anticoagulated with warfarin (25.2%). Recurrent 
non‑fatal ischemic stroke, fatal ischemic stroke, or early 
death after randomization were defined as primary efficacy 
end point. In the intention‑to‑treat cohort, 93% of the 
499 patients assigned to the closure group underwent 
the procedure. A total of 25 primary end‑point events 
occurred (non‑fatal ischemic strokes). Nine events occurred 
in patients in the closure group and 16 in patients in the 
medical therapy group (P = 0.08). In the closure group, 
there were 23.0% device‑related or procedural‑related 
serious adverse events and 21.6% in the medical therapy 
group (P = 0.65). Incidence of atrial fibrillation was not 
significantly different between the closure group and 
the medical therapy group (3.0% and 1.5%, P = 0.13, 
respectively).
In the per‑protocol cohort, primary end point in the closure 
group was at 0.46 events per 100 patient–years versus 1.30 
events in the medical group (P = 0.03). In the as‑treated 
Table 1: Contd...
Author 
(first)
Reference Year Trial Study 
size
Female/
Male
Mean 
age
Co‑morbidities Follow‑up 
(in months)
Homma 6 2017 Prospective, 
randomized study
630 298/332 59 1) arterial hypertension (60,%) 2) diabetes mellitus (28%) 
3) current smoking (29%) 4) obesity (49%) 5) sendatary 
(35%) 6) heart disease (15%) 7) prior stroke (14,7%) 8) 
heavy alcohol consumption (40%)
13
Sondergaard 19 2017 Multinational, 
randomized, 
prospective, 
controlled trial
664 265/399 45 1) arterial hypertension (25%) 2) diabetes mellitus (4%) 
3) current smoking (13%)
38
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Table 2: Specific of trials
Author Reference Inclusion criteria Exclusion criteria Size of 
ASD/VSD
Complications (%)
Carroll 4 1) aged between 18 and 
60 years 2) cryptogenic 
ischemic stroke 3) patent 
foramen ovale identified by 
TEO
mechanism for stroke 
identified
>10 mm 1) atrial fibrillation 0,2% 2) atrial flutter 
0,2% 3) cardiac perforation 0,2% 4) cardiac 
thrombus 0,2% 5) chest tightness 0,2% 6) 
deep vein thrombosis 0,2% 7) infective or 
bacterial endocarditis 0,2% 8) ischemic 
stroke 0,4% 9) pericardial effusion 0,2% 10) 
pericardial tamponnade 0,4% 11) pulmonary 
embolism 0,2% 12) residual shunt 
requiring closure 0,2% 13) sepsis 0,2% 14) 
nonsustained ventricular tachycardia 0,2% 
15) bleeding 0,4% 16) hematoma 0,2%
Furlan 5 1) aged between 18 and 
60 years 2) ischemic stroke 
or TIA within the previous 6 
months 3) patent foramen 
ovale identified by TEO 
with bubble study with a 
right‑to‑left shunt at the 
atrial level during a Valsalva 
maneuver
1) patients with other 
probable causes for a 
cardioembolic stroke such 
as clinically significant 
carotid artery stenosis 
>50%, complex aortic 
arch artheroma, clinically 
significant left ventricular 
dysfunction or left ventricular 
aneuvrysm, or atrial 
fibrillation 2) congenital 
cardiac defects not repaired 
prior to enrollment 3) 
previously implanted atrial 
septal device
>10 mm 1) atrial fibrillation 2,9% 2) strokes 1,5% 3) 
TIA 1,9%
Meier 14 1) age <60 years 2) 
presence of PFO by TEO 3) 
no other identifiable cause 
of stroke or peripheral 
thromboembolism 4) 
presence clinically or 
neurodadiogically of 
ischemic stroke or TIA 
or extracranial peripheral 
thrombolic event
NM NM 1) myocardial infarction 0,7% 2) atrial 
fibrillation 1,9% 3) bleeding 4,8% 
Windecker 21 1) Presence of PFO with 
spontaneous or provocable 
right to left shunt confirmed 
by TEO with or without 
ASA 2) TIA or stroke 
confirmed clinically 
or neuroradiologically 
3) exclusion of any 
identifiable cause for the 
thromboembolic event
Any identifiable cause for the 
thromboembolic event
>10 mm 1) device embolization 3,9% 2) cardiac 
tamponade 1,3% 3) retroperitoneal 
hematoma 1,3% 4) embolization of 
air with transient symptoms 2,6% 5) 
cerebrovascular accident<48h 1,3%
Saver 17 1) aged between 18 to 
60 years 2) presence of 
PFO confirmed by TEO 3) 
presence of cryptogenic 
ischemic stroke
Any identifiable cause for 
the stroke (largevessel 
arteriopathy, cardiac source 
of embolism, 
intrinsec small‑vessel 
disease, or an arterial 
hypercoagulable state
NM 1) Allergic drug reaction 0,2% 2) Atrial 
fibrillation 0,4% 3) Atrial flutter 0,2% 
3) Cardiac perforation 0,2% 4) Cardiac 
thrombus 0,4% 5) Chest tightness 0,2% 
6) Deep‑vein thrombosis 0,2% 7) Infective 
endocarditis 0,2% 8) Ischemic stroke 0,4% 
9) Pericardial effusion 0,2% 10) Pericardial 
tamponade 0,4% 11) Pulmonary embolism 
0,4% 12) Residual shunt requiring closure 
0,4% 13) Sepsis 0,2%
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with cryptogenic stroke and large PFO for coinciding ASA 
in preventing a recurrent stroke comparing percutaneous 
closure with anticoagulation and with antiplatelet agents. 
Five‑hundred and twenty‑four patients were randomized 
into three groups: 238 patients in the closure group, 
187 patients in the anticoagulation treatment (coumadin) 
group, and 238 patients were included in the antiplatelet 
group. All patients of the closure group received 75 mg 
of aspirin plus 75 mg of clopidogrel per day during 
3 months and then a single antiplatelet agent. Different 
closure device were used: Amplatzer PFO occluder, 
Intrasept PFO occluder, Premere device, Starflex septal 
occluder system, Amplatzer cribriform occluder, Figulla 
Flex II PFO occluder, Atriasept II occluder, Amplatzer 
ASD occluder, Figulla Flex II UNI occluder, Gore septal 
occluder, and Figulla Flex II ASD occluder. The primary 
outcome was defined as ischemic stroke. Mean follow 
up was 5.3 years. The results showed that among the 
238 patients in the closure group none had a stroke, 
whereas 14 patients of the antiplatelet group suffered 
a stroke (P < 0.001). Patients with device closure 
developed more often atrial fibrillation than patients 
Table 2: Contd...
Author Reference Inclusion criteria Exclusion criteria Size of 
ASD/VSD
Complications (%)
Mas 12 1) aged between 16 to 
60 years 2) ischemic stroke 
within the previous 6 months 
without any cause other than 
PFO 3) presence of an ASA 
or large interatrial shunt 
NM NM 1) procedural complications 5,9% 2) atrial 
fibrillation or flutter (4,6% in the closure 
group)
Mono 15 1) Presence of PFO with 
spontaneous or provocable 
right to left shunt confirmed 
by TEO with or without 
ASA 2) TIA or stroke 
confirmed clinically or 
neuroradiologically 
Any identifiable cause for the 
thromboembolic event
>10 mm 1) major bleeding (1.3%) in patients with 
anticoagulants 2) major bleeding (0,6%) in 
patients on antiplatelets 
Kitsios 8 NM NM NM NM
Argawal 1 1) presence of patent 
foramen ovale 2) stroke or 
TIA of unknown cause 
NM NM NM
Wahl 20 1) Presence of PFO with 
spontaneous or provocable 
right to left shunt confirmed 
by TEO with or without 
ASA 2) TIA or stroke 
confirmed clinically or 
neuroradiologically 
Any identifiable cause for the 
thromboembolic event 
>10 mm 1) major bleeding (1.3%) in patients with 
anticoagulants 2) major bleeding (0,6%) in 
patients on antiplatelets 
Homma 6 1) aged between 30 and 
85 2) presence of ischemic 
stroke within the previous 
30 days 3) patients rated 3 
on the Glasgow Outcome 
Scale 
1) patients with a baseline 
INR above 1,4 2) stroke 
related to a procedure or 
a cardioembolic source 3) 
patients planned to undergo 
surgery for high grade 
carotid stenosis 4) patients 
with a contraindication to 
TEE
>2 mm NM
Sondergaard 19 1) aged between 18 to 59 2) 
cryptogenic ischemic stroke 
within 180 days before 
randomization 3) presence 
of a PFO with a right to left 
shunt
1) stroke with a small, 
deep infarction (<1.5 cm 
in diameter) 2) presence 
of a typical clinical lacunar 
syndrome 2) uncontrolled 
diabetes mellitus or 
hypertension or autoimmune 
disease 3) recent history 
of alcohol or drug abuse 
4) presence of a specific 
indication for anticoagulation
NM 1) atrial fibrillation or flutter (2%) 2) 
procedure complications (5,9%) 3) major or 
fatal bleeding complication (2%)
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within the antiplatelet group (4.6% vs. 0.9%, P = 0.02). 
There was no significant difference between the groups 
in terms of serious adverse events defined as major 
bleeding and atrial fibrillation (35.7% of the patients in 
the PFO closure group and 33.2% of the patients in the 
antiplatelet‑only group, P = 0.56).
The REDUCE trial conducted by Søndergard et al.[19] 
enrolled 664 patients (of whom 81% had moderate or 
large interatrial shunts) with a mean age of 45.2 years 
and a mean follow up of 3.2 years. Patients who had 
presented a cryptogenic stroke in the previous 180 days 
were randomized into two groups, one with PFO 
closure (using the Gore Helex septal occluder or the Gore 
Cardioform septal occluder) plus antiplatelet therapy 
versus antiplatelet therapy alone. The antiplatelets agent 
used was aspirin alone or aspirin plus dipyridamole or 
clopidogrel alone. There were two primary end points, 
the first was the absence of ischemic stroke for at least 
24 months after randomization and the second was the 
incidence of cerebral infarction (clinical or imaging) at 
2 years of follow up. Recurrent clinical ischemic stroke 
occurred in 1.4% of patients who underwent PFO closure 
and in 5.4% of patients with antiplatelet only (P = 0.002). 
The second composite end point was lower in the closure 
PFO group than in the second group (5.7% vs. 11.3%, 
P = 0.04). There was no significant difference between 
the two groups concerning the incidence of silent brain 
infarction (P = 0.97). After PFO closure, atrial fibrillation 
occurred in 6.6% of patients.
Safety and efficacy of PFO closure
The rate of effective closure of the PFO in the 
CLOSURE I trial was 86.7%. Regarding serious adverse 
events there were no significant differences between the 
two groups (16.9% in the closure group vs. 16.6% in the 
medical therapy group, P = 0.90). About 1.1% of the 
closure group patients had a thrombus in the left atrium 
within 6 months of whom two had a stroke. Another 
general complication in the closure group was atrial 
fibrillation. In this trial, 5.7% of closure group patients 
had atrial fibrillation versus 0.7% of the patients in the 
medical group (P < 0.001).
In the RESPECT trial, the success rate of delivery and 
release device was 99.1%. The rate of procedure‑related 
or device‑related serious adverse events was 4.2% in 
the closure group. The atrial fibrillation rate was not 
significantly different between the groups (3% vs. 1.5%, 
P = 0.13).
In the long‑term follow up of RESPECT trial, the rate of 
pulmonary embolism in the closure group was 0.41 per 
100 patient–years and 0.11 per 100 patient–years in the 
medical group (P = 0.04).
In the PC trial, there was no device‑related thrombus in 
any patient. The difference observed between the two 
groups about atrial fibrillation was not significant, 2.9% 
in the closure group versus 1% in the medical group, 
P = 0.16.
The REDUCE trial found a significant difference 
concerning atrial fibrillation or flutter between the PFO 
closure group and the antiplatelet group (6.6% vs. 0.4%, 
P < 0.001, respectively).
The CLOSE trial reported 5.9% of device‑related 
procedure in the PFO closure group. Atrial fibrillation 
was more common in the PFO closure group than in the 
antiplatelet group (4.6% vs. 0.9%, P = 0.02, respectively). 
The rate of serious adverse events did not differ 
significantly between the two groups (P = 0.56).
Wahl et al. observed in their propensity score‑matched 
study a complete PFO closure in 82% of patients at 
6 months. However, there were cases of residual shunt, 
small in 10% of patients, moderate in 3%, and large in 5%. 
A device‑related thrombus was observed in two patients, 
resolved under anticoagulation. Major bleeding occurred 
in 1% of patients in the PFO closure group and in 2.9% 
of patients in the medically treated group (P = 0.34).
The following study did not seek to compare the different 
current management of PFO, but evaluated the long‑term 
outcomes of closure.
The study from Windecker et al.[21] was a prospective 
study with a follow up of 5 years in 80 patients with a 
mean age of 52 years. All patients had a PFO associated 
with a paradoxical embolic event (stroke, TIA, or 
peripheral embolism) and had undergone transcatheter 
closure with five different devices (Buttoned device 
for 28 patients, PFO‑STAR for 19 patients, Amplatzer 
Occluder for 14 patients, Angel‑wings Occluder for 
10 patients, and CardioSEAL for 9 patients). Twenty 
patients had an associated ASA, the remaining had 
only a PFO. The closure procedure had a complete 
closure rate at 98%. There were eight procedure‑related 
device complications. In one patient, the procedure was 
cancelled before device delivery because of laceration 
of the femoral artery during venous puncture. Device 
embolization occurred in another patient with PFO 
and a large ASA into the pulmonary artery 12 hours 
after the procedure. Cerebrovascular event occurred in 
a patient due to air embolism. Two patients presented 
embolization of the counter occluder in the pulmonary 
artery. Perforation of the right atrium occurred in 
one patient under oral anticoagulation, resulted in a 
pericardial effusion. Two patients presented cardiac 
and cerebral events due to embolization of air into the 
systemic circulation.
The role of anticoagulants
It is still an open question if anticoagulants are as effective 
as closure? In the PICSS trial, Homma et al.[7] have 
sought to evaluate the impact of antithrombotic therapies 
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by comparing them to oral anticoagulation in patients 
with cryptogenic stroke‑associated PFO. They enrolled 
630 patients with a cryptogenic stroke, 312 (49.5%) were 
randomized to warfarin and 318 (50.5%) to aspirin. The 
primary end points were recurrent ischemic stroke or 
death. In the end, there was no significant difference 
in the primary end point between patients treated with 
warfarin and those who received aspirin (P = 0.49).
Argawal et al.[1] also demonstrated that the risk of 
recurrent cerebrovascular events was lower with 
anticoagulants than with antiplatelets (RR 0.58, 95% CI, 
0.41–0.82, 12 studies, Ι² =0%).
Data from Kitsios[8] meta‑analysis showed a clear superiority 
of anticoagulants versus antiplateles in preventing recurrent 
events. (IR ratio = 0.42, 95% CI, 0.18–0.98).
In a subgroup analysis of the RESPECT trial, there 
were no differences regarding risk of recurrence 
between the closure group and patients treated with 
anticoagulants (HR, 0.64; 95% CI, 0.34–1.20; P = 0.16). 
In the CLOSE trial, 524 were randomized into three 
groups: 173 patients in the closure group, 180 patients 
in the anticoagulation (coumadin) treatment group, and 
171 patients were included in the antiplatelet group. 
In the intention‑to‑treat cohort, they observed three 
strokes in the anticoagulation group and seven strokes 
in the antiplatelet group. The authors did not proceed 
to a statistical significance because the study was not 
adequately powered to compare results in the two groups. 
However, other results are still expected in this study, 
which dates only from 2017.
Other etiologies for first‑ever and recurrent 
stroke in patients with PFO
An intensive diagnostic work‑up is needed in all patients 
with PFO and first‑ever or recurrent stroke before 
evaluation a potential closure as closure can only prevent 
PFO‑associated strokes.
In the CLOSURE I trial other etiologies could explain 
the recurrent cerebrovascular event (TIA or stroke) 
in 20 patients of the 23 in the closure group and in 
22 patients of the 29 of the medical therapy group. The 
etiologies evoked were atrial fibrillation, a clot in the left 
atrium, subcortical lacunar infarction with risk factors, 
aortic arch atheroma, migraine complex, vasculitis, 
and conversion disorder. There were 12 strokes in the 
closure group. For three of these patients, the etiology 
found was atrial fibrillation and for two of them there 
was a thrombus device‑related on the transesophageal 
echocardiogram (TEE). Regarding the medical therapy 
group, there were 13 strokes of which 1 was related to 
atrial fibrillation.
Mono et al.[15] investigated the etiology of a recurrent 
event in 308 cryptogenic stroke patients of whom 
158 patients received medical therapy (aspirin for 48%, 
clopidogrel for 2%, and oral anticoagulation for 50%) 
and150 patients had undergone percutaneous PFO 
closure. The mean follow up was 8.7 years. During the 
follow up, they observed 13 strokes and 19 TIA in the 
medical therapy group and 8 strokes and 8 TIA occurred 
in the closure group. Other etiologies were selected for 
38% of recurrent cerebrovascular events in the medical 
group: large artery disease (9%), small artery disease (6%), 
cardioembolism (13%), cerebral vasculitis (3%), and 
antiphospholipid antibody syndrome (6%). Forty‑four 
percent of recurrent cerebrovascular events had an 
etiology other than PFO in the closure group: large 
artery disease (6%), small artery disease (19%), 
cardioembolism (13%), and thrombophilic disorder (6%). 
The frequency of concurrent etiologies between the two 
groups was not significantly different (P = 0.68).
CONCLUSION
A PFO closure can only be effective in PFO‑related 
strokes, which means that an extensive diagnostic 
work‑up is needed to identify patients with “real” 
cryptogenic stroke who might derive benefit from PFO 
closure. Patients selection (e.g., inclusion of patients 
with lacunar stroke probably due to microangiopathy), 
inclusion of TIA patients as in the CLOSURE I trial, 
inclusion of TIA as endpoint event, low recurrence rates 
under prevention regimens, crossovers, procedure‑ and 
device‑related complications might explain the observed 
inconsistency of trials. Our findings are echoed by the 
recent study of Ntaios et al.[16] a meta‑analysis based on 
five trials (PC, Respect, Closure‑I, Reduce, Close) that 
found equally that PFO closure was superior to medical 
treatment in reducing ischemic stroke recurrence in 
patients with cryptogenic stroke or TIA. The analysis 
found further that the AMPLATZER PFO occluder 
and the more recent used Helex and Cardioform septal 
occluders were superior to medical treatment.
In summary, closure seems to be effective in 
patients >60 years with classical cryptogenic stroke, 
especially if there is a large shunt (Grade 2 and 3) or a 
coinciding ASA. However, we still do not know if closure is 
also effective in patients <60 years and if anticoagulants 
are as effective as closure or superior to antiplatelets, 
respectively. Atrial fibrillation is observed in up to 7% 
after closure and might be of clinical significance. Careful 
selection of clear cryptogenic stroke patients is the key 
to the success of the percutaneous closure procedure. In 
case of a recurrent event, an intensive workup is needed 
to rule out alternative causes of recurrence.
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